Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
omozygous familial hypercholesterolemia is a genetic disorder characterized by low-density lipoprotein (LDL)-receptor dysfunction, markedly elevated levels of LDL-cholesterol (LDL-C) and premature atherosclerosis.Patients are often poorly responsive to conventional lipid-lowering therapies that upregulate LDL-receptor expression. 1 Lomitapide inhibits microsomal triglyceride transfer protein, which lipidates nascent apolipoprotein (apo)B-containing lipoproteins.In a pivotal 78-week openlabel trial, lomitapide, titrated to the maximal tolerable dose, decreased LDL-C by 50% at the end of the efficacy phase (week 26) in patients with homozygous familial hypercholesterolemia. 2 The principal adverse events included gastrointestinal disturbances, hepatic enzyme elevations, and increased liver fat.Here we provide additional long-term efficacy and safety data, including an exploratory analysis of the potential metabolic consequences of hepatic fat accumulation from an extension trial (NCT00943306).Patients continued on lomitapide at the maximally tolerated dose until transition to commercial or compassionate lomitapide.Lipid-lowering therapies, including apheresis, could be modified at the investigator's discretion if LDL-C was <100 mg/dL.Both studies received institutional review board and regulatory approval, and all participants provided informed consent.Significance of the percent changes from baseline was assessed using a mixed linear model; correlations were assessed with Pearson correlation.Nineteen (mean age, 30.4 years; 10 male/9 female) of the 23 patients who completed the pivotal trial enrolled in the extension trial, and 17 completed week 126 (78 weeks pivotal + 48 weeks extension) assessments (primary efficacy end point).Three patients discontinued prematurely (relocation, elevated transaminases and excess alcohol, sudden cardiac death).The median lomitapide dose remained mostly consistent at 40 mg (range, 20-60 mg) from week 36 in the pivotal study to week 282 in the extension trial.Overall, the median treatment duration with lomitapide across both trials was 5.1 years (range, 2.1-5.7 years).Among the 17 patients who completed week 126, LDL-C decreased from 356±127 mg/dL at baseline to 189±120 mg/dL at week 126, a mean percent change of -45.5% (95% confidence interval [CI], -61.6 to -29.4; P<0.001).LDL-C reduction was maintained for the duration of the extension trial (P<0.001; Figure , A).From baseline through week 246, a total of 14 (74%) patients achieved LDL-C <100 mg/dL, and 11 (58%) patients achieved LDL-C <70 mg/dL on at least 1 occasion.LDL-C reduction was independent of residual LDL-receptor functionality.The most common adverse events reported were gastrointestinal, including diarrhea, nausea, dyspepsia, and vomiting.For most drug-related adverse events, the incidence was lower in the extension trial compared with the pivotal trial (42.1% versus 84.2%).Major adverse cardiovascular events occurred in 2 patients (sudden cardiac death and coronary artery bypass graft).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citation
Cited by
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
A Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 469
Self-citationFamilial hypercholesterolaemia
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Hegele, R. A., Santos, R. D., & Wierzbicki, A. S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.93 · Cited by 453
Self-citationSoppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
Cuchel, M., Raal, F. J., Hegele, R. A., Al-Rasadi, K., Arca, M., Averna, M., Bruckert, E., Freiberger, T., Gaudet, D., Harada-Shiba, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad197 · Cited by 359
Self-citation
Metadata
- Authors
- Blom, D. J., Averna, M. R., Meagher, E. A., du Toit Theron, H., Sirtori, C. R., Hegele, R. A., Shah, P. K., Gaudet, D., Stefanutti, C., Vigna, G. B., Larrey, D., Bloedon, L. T., Foulds, P., Rader, D. J., & Cuchel, M.
- Venue
- Circulation
- Published
- 2017-07-18
- Volume
- 136
- Issue
- 3
- Pages
- 332-335
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2734434515
- Cited by
- 140
- References
- 1
- FWCI
- 13.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. https://app.cochat.ai/papers/10.1161/circulationaha.117.028208
- The paper
- Blom, D. J., Averna, M. R., Meagher, E. A., du Toit Theron, H., Sirtori, C. R., Hegele, R. A., Shah, P. K., Gaudet, D., Stefanutti, C., Vigna, G. B., Larrey, D., Bloedon, L. T., Foulds, P., Rader, D. J., & Cuchel, M. (2017). Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation. https://doi.org/10.1161/circulationaha.117.028208
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.